Voyager Therapeutics, Inc.
VYGR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640266
No open-market purchases or sales by Voyager Therapeutics, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $122.7M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Voyager Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +24 vs. Q1 2023
- Shares held
- 26.9M
- +3.06M (+12.9%) vs. Q1 2023
- Total value
- $307.7M
- +$123.9M (+67.4%) vs. Q1 2023
- New holders
- 41
- 36 more added
- Sold out
- 17
- 21 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VYGR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 135 | $122.7M |
| Q1 2026 | 135 | $129.4M |
| Q4 2025 | 125 | $132.6M |
| Q3 2025 | 117 | $141.1M |
| Q2 2025 | 113 | $103.1M |
| Q1 2025 | 116 | $117.4M |
| Q4 2024 | 133 | $196.2M |
| Q3 2024 | 128 | $205.9M |
| Q2 2024 | 127 | $301.6M |
| Q1 2024 | 132 | $331.1M |
| Q4 2023 | 107 | $227.5M |
| Q3 2023 | 111 | $211.2M |
| Q2 2023 | 106 | $307.7M |
| Q1 2023 | 82 | $183.8M |
| Q4 2022 | 70 | $146.2M |
| Q3 2022 | 69 | $142.9M |
| Q2 2022 | 78 | $142.3M |
| Q1 2022 | 70 | $171.3M |
| Q4 2021 | 59 | $51.3M |
| Q3 2021 | 69 | $58.6M |
| Q2 2021 | 78 | $96.8M |
| Q1 2021 | 101 | $125.7M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Voyager Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 1,229,981 | $14.1M | 0.00% | +328,516+36.4% | Added |
| Farallon Capital Management, L.L.C. | 1,292,000 | $14.8M | 0.09% | +495,000+62.1% | Added |
| Vanguard Group Inc | 2,475,826 | $28.3M | 0.00% | +511,146+26.0% | Added |
| BlackRock Inc. | 2,477,400 | $28.4M | 0.00% | +1,653,613+200.7% | Added |
| Armistice Capital, LLC | 3,624,000 | $41.5M | 1.04% | +100,000+2.8% | Added |
| EcoR1 Capital, LLC | 3,851,507 | $44.1M | 1.16% | 00.0% | Unchanged |
| TRV GP III, LLC | 0 | $0 | 0.00% | −3,185,291−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −101,781−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −90,885−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −82,326−100.0% | Sold out |
| HarbourVest Partners LLC | 0 | $0 | 0.00% | −61,776−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −23,000−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −19,048−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −16,623−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −16,300−100.0% | Sold out |
| Hershey Trust Co | 0 | $0 | 0.00% | −12,580−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −12,527−100.0% | Sold out |
| Gamco Investors, Inc. Et Al | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −6,224−100.0% | Sold out |
| Psagot Value Holdings Ltd. / (Israel) | 0 | $0 | 0.00% | −416−100.0% | Sold out |